Lais Da Silva

Lais Da Silva

Auto-generated profile, based on publicly available information

Lais Da Silva

Division of Clinical Pharmacology, Department of Medicine IUSM Indianapolis Indiana USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2020 in Neuroscience Letters
Verified
Journal Article
Closed access
JWJenny Wilkerson
Jenny Wilkerson
JJJinmai Jiang
Jinmai Jiang
JFJasmine S. Felix
Jasmine S. Felix
JBJulie K. Bray
Julie K. Bray
LSLais da Silva
Lais da Silva
Thomas SchmittgenThomas Schmittgen
Thomas Schmittgen

18 July 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
BCBrian Cicali
Brian Cicali
LSLais Da Silva
Lais Da Silva
ASAmir Sarayani
Amir Sarayani
KLKarthik Lingineni
Karthik Lingineni
MPMichelle Pressly
Michelle Pressly
Rodrigo CristofolettiRodrigo Cristofoletti
Rodrigo Cristofoletti

15 May 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
ASAditi Shendre
Aditi Shendre
XLXiaofu Liu
Xiaofu Liu
CCChienWei Chiang
ChienWei Chiang
AGAndrew Goodwin
Andrew Goodwin
SOSamuel‐Richard Oteng
Samuel‐Richard Oteng
LLLiang Li
Liang Li
The use and misuse of opioids has surged in the past decade, with nearly half of the users being female. Although opioid use is lower among pregnant women, trends mirror the general population. While pediatric exposures largely occur through prescriptions. This review presents a novel landscape analysis of pharmacology knowledge gaps in opioids in the maternal and pediatric populations. We queried PubMed for studies on 27 opioids, focusing on pharmacokinetics (PK), and pharmacoepidemiology (PE) or clinical trials (CT) in maternal and pediatric populations. English‐language publications were included, and data were synthesized to identify gaps. Additionally, MarketScan claims data and United States Food and Drug Administration (FDA) drug labels were analyzed to compare scientific evidence, opioid prescriptions/orders, and FDA recommendations. Morphine, fentanyl, methadone, and buprenorphine are the most researched opioids in PK and PE/CT literature in both populations, but hydrocodone, oxycodone, and codeine are the most prescribed. Nine opioids lack FDA labels, and four of the 18 labeled drugs lack any human data. Hydrocodone, oxycodone, and codeine labels include lactation‐focused PK information, with some pediatric clinical data for the latter two. Seven opioids lack PK and PE/CT studies in the maternal population, and PK research is absent for seven opioids, and PE/CT data is lacking for eight opioids in the pediatric population. PK studies often focus on labor, delivery, and lactation accompanied by neonatal data, whereas pregnancy research mainly occurs in PE studies. In pediatric populations, study types are evenly distributed among children, but PE studies focus more on adolescents. Drug concentration is the most reported parameter in PK studies, and neonatal opioid withdrawal syndrome (NOWS) is a key outcome in both PK and PE studies. NOWS is also researched more using real‐world data, whereas neurodevelopmental outcomes are often captured in prospective observational studies. There is substantial disparity between the most commonly researched and prescribed opioids. In particular, the opioid pharmacology knowledge gaps are larger in pregnant women and for the highly prescribed opioids hydrocodone and oxycodone. The limited human data in FDA labels underscores the need for additional studies. Studies using real‐world data can potentially help address these gaps.